DRM 02
Alternative Names: DRM-02; VAL-002Latest Information Update: 26 Feb 2020
Price :
$50 *
At a glance
- Originator QLT
- Developer Dermira
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Plaque psoriasis; Rosacea
Most Recent Events
- 20 Feb 2020 Dermira has been acquired by Eli Lilly and Company
- 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
- 04 Mar 2016 Discontinued - Phase-II for Atopic dermatitis in Canada (Topical)